Publications by authors named "M Fouassier"
Article Synopsis
- - Infusion of von Willebrand factor (VWF) and factor VIII (FVIII) can lead to the development of anti-VWF antibodies, complicating management of bleeding in patients with type 3 von Willebrand disease.
- - A systematic review identified 15 cases where patient management varied, with treatments including continuous FVIII infusion, recombinant FVIIa, and other strategies.
- - Emicizumab, a bispecific monoclonal antibody, was used off-label in three cases and proved effective in managing a complex local case, highlighting its potential as a treatment option for patients with allo-immunisation.
Introduction: Acquired von Willebrand syndrome (AVWS) is a rare haemorrhagic disorder. The prophylaxis and treatment of bleeding before surgery are complex. Since 2018, a new recombinant VWF (rVWF) concentrate that contains no factor VIII (FVIII) but a high amount of high molecular weight VWF multimers has been available in France.
View Article and Find Full Text PDFIntroduction: The entity entitled bleeding disorder of unknown cause (BDUC) qualifies individuals displaying a mild haemorrhagic profile but normal routine coagulation tests. This study was designed to evaluate whether collagen-binding assay for von Willebrand Factor (VWF) measurement (VWF:CB) could allow to diagnose VW disease in such patients.
Methods: A large screening was conducted prospectively in two University Hospitals, using the bleeding assessment tool (BAT) recommended by the International Society of Thrombosis and Hemostasis.
Accurate assessment of platelet secretion is essential for the diagnosis of inherited or acquired platelet function disorders and more specifically in identifying δ-storage pool disease. Mepacrine, a fluorescent dye, specifically accumulates in platelet δ-granules. The mepacrine flow cytometry (mepacrine FCM) assay has been used for more than half a century in the clinical laboratory as a diagnostic tool for platelet δ-granule disorders.
View Article and Find Full Text PDFArticle Synopsis
- Von Willebrand disease (VWD) is the most common inherited bleeding disorder, but data on how patients are treated during hospitalizations is limited.
- A study named Hopscotch-WILL looked at 988 VWD patients over four years to understand their treatment and factors driving the use of coagulation factors during hospital stays.
- Results showed that 15% of patients were hospitalized needing von Willebrand factor treatment, with low levels of VWF and FVIII being significant, and usage varied based on VWD type and the reason for hospitalization.